Contact SCGE




Clinical Trial Report

Gene Therapy Trial Report

Summary

Study Assessing Left Ventricular Administration of a Genetic Medicine Directing Organ Regeneration in Heart Failure


NCTID NCT06831825 (View at clinicaltrials.gov)
Description
Development Status Active
Indication Heart Failure With Reduced Ejection Fraction
Disease Ontology Term DOID:9651
Compound Name YAP101
Compound Description AAV9-Sav-shRNA
Sponsor YAP Therapeutics, Inc.
Funder Type Industry
Recruitment Status
Not yet recruiting
Enrollment Count 24
Results Posted Not Available

Therapy Information


Target Gene/Variant SAV1
Therapy Type Gene transfer
Therapy Route In-vivo
Mechanism of Action Gene inactivation
Route of Administration Transendocardial
Drug Product Type Viral vector
Target Tissue/Cell Cardiomyocyte
Delivery System Viral transduction
Vector Type AAV9
Editor Type none
Dose 1 5.0E12 vg
Dose 2 1.0E13 vg
Dose 3 5.0E13 vg
Dose 4
Dose 5

Study Record Dates


Current Stage Phase1
Submit Date 2025-01-23
Completion Date 2027-06
Last Update 2025-02-18

Participation Criteria


Eligible Age 18 Years - 79 Years
Standard Ages Adult, Older adult
Sexes Eligible for Study ALL

Locations


No.of Trial Sites
Locations

Regulatory Information


Has US IND True
FDA Designations
Recent Updates

Resources/Links